Sustained delivery formulations of risperidone compounds
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-047/34
A61K-031/519
A61K-009/00
A61K-047/32
A61K-047/22
출원번호
US-0602058
(2008-02-13)
등록번호
US-10010612
(2018-07-03)
국제출원번호
PCT/US2008/001928
(2008-02-13)
§371/§102 date
20100630
(20100630)
국제공개번호
WO2008/153611
(2008-12-18)
발명자
/ 주소
Dadey, Eric
Li, Qi
Lindemann, Christopher
출원인 / 주소
Indivior UK Limited
대리인 / 주소
Mintz Levin Cohn Ferris Glovsky and Popeo, P.C.
인용정보
피인용 횟수 :
0인용 특허 :
134
초록▼
The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained
The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid, and risperidone, a metabolite, or a prodrug thereof.
대표청구항▼
1. A flowable composition comprising: 10 wt % to 20 wt % of risperidone base in a solution comprising (i) 40 wt % to 50 wt % of an 80/20 poly(DL-lactide-co-glycolide) with a carboxylic acid end group, and (ii) 50 wt % to 60 wt % of N-methyl-2-pyrrolidone. 2. The composition of claim 1, comprising ab
1. A flowable composition comprising: 10 wt % to 20 wt % of risperidone base in a solution comprising (i) 40 wt % to 50 wt % of an 80/20 poly(DL-lactide-co-glycolide) with a carboxylic acid end group, and (ii) 50 wt % to 60 wt % of N-methyl-2-pyrrolidone. 2. The composition of claim 1, comprising about 60 mg of risperidone base. 3. The composition of claim 1, comprising about 90 mg of risperidone base. 4. The composition of claim 1, comprising about 120 mg of risperidone base. 5. The composition of claim 1, wherein the composition produces a maximum plasma concentration (Cmax) of risperidone and/or 9-hydroxyrisperidone within about 2 hours after injection into a patient. 6. The composition of claim 1, wherein the composition produces a steady state plasma level of risperidone and/or 9-hydroxyrisperidone within about three days after injection into a patient. 7. The composition of claim 1, wherein the composition produces a risperidone and/or 9-hydroxyrisperidone concentration of at least 15.8 ng/mL for about 28 days after injection into a patient. 8. The composition of claim 1, wherein the composition produces a linear sustained release of risperidone and/or 9-hydroxyrisperidone for at least 28 days. 9. The composition of claim 1, consisting of the risperidone base, the 80/20 poly(DL-lactide-co-glycolide) with the carboxylic acid end group, and the N-methyl-2-pyrrolidone. 10. The composition of claim 1, consisting of the risperidone base, the 80/20 poly(DL-lactide-co-glycolide) with the carboxylic acid end group, and the N-methyl-2-pyrrolidone. 11. The composition of claim 1, wherein the composition produces a steady state plasma level of risperidone and/or 9-hydroxyrisperidone from about three days to about forty-two days after injection into a patient. 12. The composition of claim 11, wherein the steady state plasma level of risperidone and/or 9-hydroxyrisperidone is from about 28.9 ng/ml to about 50.7 ng/ml. 13. The composition of claim 1, wherein the composition provides an AUCDayo-1 of risperidone and/or 9-hydroxyrisperidone from about 63.1 ng·day/ml to about 111.7 ng·day/ml. 14. The composition of claim 1, wherein the composition provides an AUCDay0-42 of risperidone and/or 9-hydroxyrisperidone from about 1243.3 ng·day/ml to about 2238.9 ng·day/ml. 15. The composition of claim 1, wherein the composition provides an AUCDay0-56 of risperidone and/or 9-hydroxyrisperidone from about 1417.6 ng·day/ml to about 3049.2 ng·day/ml. 16. The composition of claim 1, wherein a dose normalized AUCDay0-42 of risperidone and/or 9-hydroxyrisperidone from about 15.9 ng·day/ml·mg to about 20.9 ng·day/ml·mg. 17. The composition of claim 1 having a volume from about 0.75 ml to about 1.0 ml. 18. A flowable composition comprising: (i) 1 wt % to 30 wt % of risperidone base; (ii) 20 wt % to 60 wt % of an 80/20 poly(DL-lactide-co-glycolide) with a carboxylic acid end group; and (iii) 30 wt % to 70 wt % of N-methyl-2-pyrrolidone. 19. The composition of claim 18, wherein the composition provides a linear sustained release of risperidone and/or 9-hydroxyrisperidone for at least 28 days. 20. The composition of claim 18, comprising about 60 mg to about 120 mg of risperidone base. 21. The composition of claim 18, wherein the composition provides (i) a maximum plasma concentration (Cmax) of risperidone and/or 9-hydroxyrisperidone occurs within about 2 hours after injection into a patient and (ii) a linear sustained release of risperidone and/or 9-hydroxyrisperidone for at least 28 days after injection into a patient. 22. The composition of claim 18, wherein the composition provides a risperidone and/or 9-hydroxyrisperidone concentration of at least 15.8 ng/mL for at least 28 days after injection into a patient. 23. The composition of claim 18, wherein the composition produces a steady state plasma level of risperidone and/or 9-hydroxyrisperidone about three days after injection into a patient. 24. The composition of claim 18, wherein the composition produces a risperidone or 9-hydroxyrisperidone concentration of at least 15.8 ng/mL for at least 28 days after injection into a patient. 25. The composition of claim 18, consisting of the risperidone base, the 80/20 poly(DL-lactide-co-glycolide) with the carboxylic acid end group, and the N-methyl-2-pyrrolidone. 26. The composition of claim 18 having a volume from about 0.75 ml to about 1.0 ml. 27. A method of forming a biodegradable implant in situ in a patient in need thereof comprising the steps of: (a) injecting the flowable composition of claim 1 into the body of the patient; and(b) allowing the N-methyl-2-pyrrolidone to dissipate to produce the implant in the body of the patient. 28. A composition comprising about 15 wt % of risperidone base in a solution comprising: (i) about 45 wt % of an 80/20 poly(DL-lactide-co-glycolide) with a carboxylic acid end group; and (ii) about 55 wt % of N-methyl-2-pyrrolidone. 29. The composition of claim 28, comprising about 60 mg of risperidone base. 30. The composition of claim 28, comprising about 90 mg of risperidone base. 31. The composition of claim 28, comprising about 120 mg of risperidone base. 32. The composition of claim 28 having a volume from about 0.75 ml to about 1.0 ml.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (134)
Kennis Ludo E. J. (Turnhout BEX) Vandenberk Jan (Beerse BEX), 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles.
Lhner Manfred (Bonn DEX) Posselt Klaus (Bonn DEX) Vogtle-Junkert Ute (Alfter DEX) Wagener Hans H. (Meckenheim DEX), Agents for the treatment of severe pain and preparation of said agents.
Alan M. Polson ; Deryl D. Swanbom ; Richard L. Dunn ; Charles P. Cox ; Richard L. Norton ; Bryan K. Lowe ; Kenneth S. Peterson, Biodegradable implant precursor.
Dunn Richard L. (451 Boardwalk Dr. RLD ; Apt. 501 Fort Collins CO 80526) English James P. (2500 Melinda Cir. Birmingham AL 35214) Cowsar Donald R. (4657 Round Forest Dr. Birmingham AL 35213) Vanderbi, Biodegradable in-situ forming implants and methods of producing the same.
Dunn Richard L. (Fort Collins CO) English James P. (Birmingham AL) Cowsar Donald R. (Birmingham AL) Vanderbilt David P. (Birmingham AL), Biodegradable in-situ forming implants and methods of producing the same.
Dunn Richard L. (Fort Collins CO) Tipton Arthur J. (Fort Collins CO) Southard George L. (Fort Collins CO) Rogers Jack A. (Fort Collins CO), Biodegradable polymer composition.
Langer Robert S. (Somerville MA) Rosen Howard (Montara CA) Linhardt Robert J. (Iowa City IA) Leong Kam (Cambridge MA), Bioerodible polyanhydrides for controlled drug delivery.
Gavin, Paul; Gianello, Robert; Ogru, Esra, Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof.
Temtsin Krayz, Galia; Averbuch, Maryana; Zelkind, Ilya; Gitis, Larisa, Compositions comprising lipophilic active compounds and method for their preparation.
Drust Eugene G. (Norwich NY) Kasting Gerald B. (Wyoming OH) Smith Ronald L. (West Chester OH) Szkutak Joan B. (West Chester OH), Compositions for the transdermal delivery of pharmaceutical actives.
Chandrashekar Bhagya L. ; Zhou Mingxing ; Jarr Eileen M. ; Dunn Richard L., Controlled release liquid delivery compositions with low initial drug burst.
Gibson, John W.; Miller, Stacey S.; Middleton, John C.; Tipton, Arthur J., High viscosity liquid controlled delivery system and medical or surgical device.
John W. Gibson ; Stacey A. Sullivan ; John C. Middleton ; Arthur J. Tipton, High viscosity liquid controlled delivery system and medical or surgical device.
Tice Thomas R. (Birmingham AL) Lewis Danny H. (Gardendale AL) Cowsar Donald R. (Birmingham AL) Beck Lee R. (Birmingham AL), Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents.
Cohen Smadar (Petach-Tickva ILX) Bano Carmen (Valencia PA ESX) Visscher Karyn B. (State College PA) Chow Marie (Brookline MA) Allcock Harry R. (State College PA) Langer Robert S. (Newton MA), Ionically cross-linked polymeric microcapsules.
Michal, Eugene T.; Lerner, Daniel J.; Pollman, Matthew J., Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens.
Michal, Eugene T.; Lerner, Daniel J.; Pollman, Matthew J., Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens.
Sinclair John D. (Espoo FIX), Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administer.
Steven G. Wright ; Michael E. Rickey ; J. Michael Ramstack ; Shawn L. Lyons ; Joyce M. Hotz, Method for preparing microparticles having a selected polymer molecular weight.
Wright Steven G. ; Rickey Michael E. ; Ramstack J. Michael ; Lyons Shawn L. ; Hotz Joyce M., Method for preparing microparticles having a selected polymer molecular weight.
Wright, Steven G.; Rickey, Michael E.; Ramstack, J. Michael; Lyons, Shawn L.; Hotz, Joyce M., Method for preparing microparticles having a selected polymer molecular weight.
Mesens Jean (Wechelderzande BEX) Rickey Michael E. (Loveland OH) Atkins Thomas J. (Cincinnati OH), Method of inhibiting neurotransmitter activity using microencapsulated 3-piperidiny2-substituted 1,2-benzisoxazoles and.
Cleland Jeffrey L. (San Carlos CA) Lim Amy (San Bruno CA) Powell Michael Frank (San Francisco CA), Methods and compositions for microencapsulation of adjuvants.
Gole Dilip J. (Ann Arbor MI) Levinson R. Saul (Chesterfield MO) Wilkinson Paul K. (Ann Arbor MI) Davies J. Desmond (Grosse Pointe Farms MI), Pharmaceutical and other dosage forms.
Dunn, Richard L.; Garrett, John Steven; Ravivarapu, Harish; Chandrashekar, Bhagya L, Polymeric delivery formulations of leuprolide with improved efficacy.
Dunn, Richard L.; Garrett, John Steven; Ravivarapu, Harish; Chandrashekar, Bhagya L., Polymeric delivery formulations of leuprolide with improved efficacy.
Michael E. Rickey ; J. Michael Ramstack ; Danny H. Lewis, Preparation of biodegradable, biocompatible microparticles containing a biologically active agent.
Rickey Michael E. ; Ramstack J. Michael ; Lewis Danny H., Preparation of biodegradable, biocompatible microparticles containing a biologically active agent.
Rickey Michael E. ; Ramstack J. Michael ; Lewis Danny H., Preparation of biodegradable, biocompatible microparticles containing a biologically active agent.
Rickey Michael E. ; Ramstack J. Michael ; Lewis Danny H., Preparation of biodegradable, biocompatible microparticles containing a biologically active agent.
Rickey Michael E. ; Ramstack J. Michael ; Lewis Danny H. ; Mesens Jean,BEX, Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent.
Ramstack, J. Michael; Riley, M. Gary I.; Zale, Stephen E.; Hotz, Joyce M.; Johnson, Olufunmi L., Preparation of injectable suspensions having improved injectability.
Venkatasubramanian, Radhakrishnan Tarur; Govind, Sathe Dhananjay; Vasantrao, Suryavanshi Chandrakant, Process for the preparation of anti-psychotic 3-[2-[-4-(6-fluoro-1,2-benziosoxazol-3-yl)-1-piperidinyl] ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one.
Kino Shigemi (Fukuoka JPX) Osajima Tomonori (Fukuoka JPX) Mizuta Hiroaki (Fukuoka JPX), Sustained release microsphere preparation containing antipsychotic drug and production process thereof.
Richard Sterling Tuthill ; William Theodore Bechtel, II ; Jeffrey Arthur Benoit ; Stephen Hugh Black ; Robert James Bland ; Guy Wayne DeLeonardo ; Stefan Martin Meyer ; Joseph Charles Taura ;, Swozzle based burner tube premixer including inlet air conditioner for low emissions combustion.
Chen Yu-Ling (Cupertino CA) Chun Leslie L. (Palo Alto CA) Enscore David J. (Sunnyvale CA), Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.